OncoBeta GmbH epidermal radioisotope therapy
- Nov. 15, 2018
-- Garching n. Munich, Germany,
(June 15, 2018) - OncoBeta GmbH®
, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is pleased to announce that it has entered an exclusive distribution agreement with Tautomer (PTY) LTD / Nativa (PTY) LTD
of South Africa to start Rhenium-SCT®
(Skin Cancer Therapy) treatments in South Africa and subsequently service the African Continent. This agreement represents another milestone in the development of OncoBeta's growing global distribution network.
Under the terms of the agreement, Tautomer and Nativa will employ its extensive knowledge of African markets, sales and marketing expertise and strong network to introduce, distribute and service the Rhenium-SCT®
therapy. The distribution agreement includes all geographies of the African continent starting with South Africa.
The initial Rhenium-SCT®
treatment center in South Africa will be implemented by internationally acclaimed Nuclear Medicine Specialist Prof. Mike Sathekge of the University of Pretoria.
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Approximately 80% of non-melanoma skin cancers are basal cell carcinomas or squamous cell carcinomas. South Africa, together with Australia, has one of the highest incidence rates of basal and squamous cell carcinomas in the world.
"This partnership and cooperation is a part of our strategy to increase availability of our new and innovative skin cancer therapy to patients, especially in South Africa and beyond," said Shannon D. Brown III, CEO and Managing Director of OncoBeta GmbH. "We look forward to making the Rhenium-SCT®
more widely available to physicians and patients as we expand on this partnership and extend our reach across the African continent."About the Rhenium-SCT® (Skin Cancer Therapy)
is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT®
utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT®
compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT®
with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-
art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT®
(Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the EU.
Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT®
significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.
Find out more about the Rhenium-SCT®